TP53 and glioblastoma: Regarding TP53 mutations, they are reported to be more prevalent in diffuse astrocytomas (74%), anaplastic astrocytomas (65%), and secondary glioblastomas (62%) compared to oligodendrogliomas (16%) or anaplastic oligodendrogliomas (9%) [12].